Treatment of rheumatoid arthritis: a global perspective on the use of antirheumatic drugs

被引：50

作者：

Sokka, Tuulikki ^{[1
,2
]}

Envalds, Minja ^{[3
]}

Pincus, Theodore ^{[4
]}

机构：

[1] Jyvaskyla Cent Hosp, Jyvaskyla 40620, Finland

[2] Medcare Oy, Aanekoski, Finland

[3] Univ Kuopio, Sch Med, FIN-70211 Kuopio, Finland

[4] NYU, Hosp Joint Dis, New York, NY USA

来源：

MODERN RHEUMATOLOGY | 2008年 / 18卷 / 03期

关键词：

Rheumatoid arthritis; DMARDs; Methotrexate;

D O I：

10.1007/s10165-008-0056-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Modern therapy for rheumatoid arthritis (RA) is based on knowledge of the severity of the natural history of the disease. RA patients are approached with early and aggressive treatment strategies, methotrexate as an anchor drug, biological targeted therapies in those with inadequate response to methotrexate, and "tight control,'' aiming for remission and low disease activity according to quantitative monitoring. This chapter presents a rationale for current treatment strategies for RA with antirheumatic drugs, a review of published reports concerning treatments in clinical cohorts outside of clinical trials, and current treatments at 61 sites in 21 countries in the QUEST-RA database.

引用

页码：228 / 239

页数：12

共 103 条

[1]

AHO K, 1989, CLIN EXP RHEUMATOL, V7, P287

[2] The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses [J].

Aletaha, D ;

Smolen, JS .

RHEUMATOLOGY, 2002, 41 (12) :1367-1374

[3]

ALLBUTT TC, 1907, SYSTEM MED

[4] THE AMERICAN-RHEUMATISM-ASSOCIATION 1987 REVISED CRITERIA FOR THE CLASSIFICATION OF RHEUMATOID-ARTHRITIS [J].

ARNETT, FC ;

EDWORTHY, SM ;

BLOCH, DA ;

MCSHANE, DJ ;

FRIES, JF ;

COOPER, NS ;

HEALEY, LA ;

KAPLAN, SR ;

LIANG, MH ;

LUTHRA, HS ;

MEDSGER, TA ;

MITCHELL, DM ;

NEUSTADT, DH ;

PINALS, RS ;

SCHALLER, JG ;

SHARP, JT ;

WILDER, RL ;

HUNDER, GG .

ARTHRITIS AND RHEUMATISM, 1988, 31 (03) :315-324

[5]

Arthur V, 2003, RHEUMATOLOGY, V42, P31

[6] Rheumatoid arthritis in Dubai - delayed diagnosis and low usage of disease modifying antirheumatic drugs [J].

Badsha, Humeira ;

Kong, K. Ooi ;

Tak, P. P. .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) :835-835

[7]

Bergström U, 1999, SCAND J RHEUMATOL, V28, P160

[8]

Bombardier C, 2002, ARTHRITIS RHEUM-US, V46, pS344

[9] Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years - Results from a large observational inception study [J].

Bukhari, MAS ;

Wiles, NJ ;

Lunt, M ;

Harrison, BJ ;

Scott, DGI ;

Symmons, DPM ;

Silman, AJ .

ARTHRITIS AND RHEUMATISM, 2003, 48 (01) :46-53

[10] Trends in disease modifying antirheumatic drug prescription in early rheumatoid arthritis are influenced more by hospital setting than patient or disease characteristics [J].

Carli, C. ;

Ehlin, A. G. C. ;

Klareskog, L. ;

Lindblad, S. ;

Montgomery, S. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (08) :1102-1105

← 1 2 3 4 5 6 7 8 9 10 →